Pyridam Farma Tbk PT
IDX:PYFA

Watchlist Manager
Pyridam Farma Tbk PT Logo
Pyridam Farma Tbk PT
IDX:PYFA
Watchlist
Price: 206 IDR -4.63% Market Closed
Market Cap: 2.3T IDR
Have any thoughts about
Pyridam Farma Tbk PT?
Write Note

Pyridam Farma Tbk PT
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pyridam Farma Tbk PT
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Pyridam Farma Tbk PT
IDX:PYFA
Net Income (Common)
-Rp254B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Tempo Scan Pacific Tbk PT
IDX:TSPC
Net Income (Common)
Rp1.3T
CAGR 3-Years
16%
CAGR 5-Years
21%
CAGR 10-Years
8%
Kalbe Farma Tbk PT
IDX:KLBF
Net Income (Common)
Rp3.1T
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
4%
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Net Income (Common)
Rp193.9B
CAGR 3-Years
-12%
CAGR 5-Years
-2%
CAGR 10-Years
6%
Soho Global Health Tbk PT
IDX:SOHO
Net Income (Common)
Rp371.3B
CAGR 3-Years
29%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Kimia Farma Tbk PT
IDX:KAEF
Net Income (Common)
-Rp1.7T
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pyridam Farma Tbk PT
Glance View

Market Cap
2.3T IDR
Industry
Pharmaceuticals

PT Pyridam Farma Tbk engages in the production and development of pharmaceutical medicines, and trading of medical supplies. The company is headquartered in Jakarta, Dki Jakarta and currently employs 1,539 full-time employees. The company went IPO on 2001-10-16. The firm operates through two segments: Pharmaceutical Products and Toll Manufacturing Services, and Medical Device Products. Its business consists of production and/or distribution of modern and traditional medicines and distribution of medical devices, such as laboratory equipment and PCR test kits. The company offers products across consumer health, prescription, pyfaesthetic and biomedilab categories. The company produces various kinds of pharmaceuticals products ranging from antibiotics, vitamins and health supplements. The firm offers its products in the form of effervescent tablets, capsules, caplets, syrups and creams. Its prescription production has several properties, such as anti-infection, anti-inflammatory, anti-parkinsonian, anti-epileptic, and other indications. The company provides toll manufacturing services to produce products owned by the Company’s partner companies in accordance with predetermined specifications.

PYFA Intrinsic Value
113.32 IDR
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Pyridam Farma Tbk PT's Net Income (Common)?
Net Income (Common)
-254B IDR

Based on the financial report for Sep 30, 2024, Pyridam Farma Tbk PT's Net Income (Common) amounts to -254B IDR.

What is Pyridam Farma Tbk PT's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
-330%

Over the last year, the Net Income (Common) growth was -330%.

Back to Top